Taro Pharmaceuticals USA, Inc. BALANCE SHEET				
	Mai	ch 31, 2025	M	arch 31, 2024
			ollars	
	- 10-	Unau	dited	
ASSETS OUR DESIT ASSETS				
CURRENT ASSETS	\$	7 750 251	\$	24 140 707
Cash Marketable Securities	Þ	7,759,251	D.	24,149,707 678,309
Trade:Open Accounts+Ch.Rec.		132,004,677		123,555,272
Other receivables and prepaid expense:				
Accounts Receivable - Other		25,511,944		8,479,454
Deferred Taxes		C 574 CO5		0.701.041
Corporate Taxes Receivable		6,574,605 1,102,423,986		8,701,841 959,382,298
Intercompany receivables Intercompany Loan receivables		15,162,082		17,709,096
Total Other receivables and prepaid expense:		1,149,672,617		994,272,689
Total Other receivables and prepare expense.				
Inventories		60,433,593		111,456,198
TOTAL CURRENT ASSETS		1,349,870,138		1,254,112,175
LONG-TERM RECEIVABLES AND OTHER ASSETS				
Goodwill		10,040,307		10,040,307
Long term investments		5,111,363		1,329,362
Long term marketable securities		6,776,308		7,322,380
FIXED ASSETS		E0.050.450		(0.440.004
Cost		70,253,472		69,119,921
Less-Accum Depreciation		26,164,059	-	(41,956,541) 27,163,380
INTANGIBLE ASSETS AND DEFERRED COSTS, NET		20,104,037		27,103,300
INTANGIBLE ASSETS AND DEFERRED COSTS, NET		11,124,000		55,619,999
OTHER ASSETS AND DEFERRED COSTS, NET		11,124,000		48,263,262
	1			
TOTAL ASSETS	\$	1,409,086,175	\$	1,403,850,865
				1,100,000,000
			-	1,200,000,000
Taro Pharmaceuticals USA, Inc.			•	1,100,000,000
Taro Pharmaceuticals USA, Inc. BALANCE SHEET	Mar	ch 31, 2025		arch 31, 2024
	_Mar	ch 31, 2025 US D	М	
	_Mar		M ollars	
BALANCE SHEET	Mar	US D	M ollars	
	Mar	US D	M ollars	
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES	Mar 	US D	M ollars	
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers		US Do Unau	M ollars	arch 31, 2024
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities:		US Do Unau	M ollars	arch 31, 2024
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve	\$	US Do Unau 5,910,718	M ollars	arch 31, 2024 3,950,812
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables	\$	US Do Unau 5,910,718	M ollars	arch 31, 2024 3,950,812 1,188,785,528
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Loan Payable	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451	M ollars	3,950,812 1,188,785,528 152,616,160
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Loan Payable Accrued Expenses Payable - Others	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451 192,952,628	M ollars	3,950,812 1,188,785,528 152,616,160 202,039,695
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Loan Payable Accrued Expenses Payable - Others Taxes Payable	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451	M ollars	3,950,812 1,188,785,528 152,616,160 202,039,695 19,064
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Loan Payable Accrued Expenses Payable - Others Taxes Payable	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451 192,952,628 4,781	M ollars	3,950,812 1,188,785,528 152,616,160 202,039,695 19,064
LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Loan Payable Accrued Expenses Payable - Others Taxes Payable TOTAL Other current liabilities	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451 192,952,628 4,781	M ollars	3,950,812 1,188,785,528 152,616,160 202,039,695 19,064 \$1,547,411,259
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Payables Accrued Expenses Payable - Others Taxes Payable TOTAL Other current liabilities Amount Accrued/ Other long term	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451 192,952,628 4,781 1,673,763,714	M ollars	3,950,812 1,188,785,528 152,616,160 202,039,695 19,064 \$ 1,547,411,259 2,830,362
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Payables Accrued Expenses Payable - Others Taxes Payable TOTAL Other current liabilities Amount Accrued/ Other long term TOTAL LONG TERM LIABILITIES	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451 192,952,628 4,781 1,673,763,714	M ollars	3,950,812 1,188,785,528 152,616,160 202,039,695 19,064 \$ 1,547,411,259 2,830,362 2,830,362
LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Loan Payable Accrued Expenses Payable - Others Taxes Payable TOTAL Other current liabilities Amount Accrued/ Other long term IOTAL LONG TERM LIABILITIES SHAREHOLDERS' EQUITY	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451 192,952,628 4,781 1,673,763,714 1,575,363 1,575,363 (266,252,902)	M ollars	3,950,812 1,188,785,528 152,616,160 202,039,695 19,064 \$1,547,411,259 2,830,362 2,830,362 (146,390,756)
BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Loan Payable	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451 192,952,628 4,781 1,673,763,714 1,575,363 1,575,363	M ollars	3,950,812 1,188,785,528 152,616,160 202,039,695 19,064 \$1,547,411,259 2,830,362 2,830,362 (146,390,756)
LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Loan Payable Accrued Expenses Payable - Others Taxes Payable TOTAL Other current liabilities Amount Accrued/ Other long term IOTAL LONG TERM LIABILITIES SHAREHOLDERS' EQUITY	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451 192,952,628 4,781 1,673,763,714 1,575,363 1,575,363 (266,252,902)	M ollars	arch 31, 2024
LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable: Suppliers Other current liabilities: Returns reserve Intercompany Payables Intercompany Loan Payable Accrued Expenses Payable - Others Taxes Payable TOTAL Other current liabilities Amount Accrued/ Other long term TOTAL LONG TERM LIABILITIES SHAREHOLDERS' EQUITY	\$	US Do Unau 5,910,718 1,270,538,136 204,357,451 192,952,628 4,781 1,673,763,714 1,575,363 1,575,363 (266,252,902)	M ollars	3,950,812 1,188,785,528 152,616,160 202,039,695 19,064 \$1,547,411,259 2,830,362 2,830,362 (146,390,756)

Taro Pharmaceuticals USA, Inc. STATEMENT OF OPERATIONS	М	arch 31, 2025	Ma	arch 31, 2024
	-	US D	ollars	
),=====	Unau	dited	
Sales - Income	\$	326,415,520	\$	331,308,750
Cost of Sales		244,251,401		237,436,030
Gross Profit		82,164,119		93,872,720
Research & Development		3,734,829		2,377,154
Selling and Marketing Expenses		25,802,990		28,525,847
General and Administrative Expenses		80,104,431		43,966,630
Operating Income (Loss)	1 1 2 1	(27,478,131)	S - 150	19,003,089
Financial Expenses		9,382,873		7,273,643
Other Income		34,716,688		39,312,919
Profit/(Loss) before taxes on Income		(71,577,692)		(27,583,473)
Taxes on Income		48,269,523		6,396,580
Net (loss) income for the period	\$	(119,847,215)	\$	(33,980,053)

VP, Chief Financial Officer

Date of Approval

Taro Pharmaceuticals USA, Inc.

Statements of Changes In SHAREHOLDERS' EQUITY

The second	- I		THE THE THE THE	TECHNICAL PROPERTY.		-	TOTAL
		Capit	lal	Comprehensi		Earnings	Shareholders'
				(Loss) Incom	e		Equity
				US Dollars			
				Unaudited			
¥	145,000	Ð	200 272 025	9	9 (101	(400 401 14C) ¢	(EOF OFF OFF)
÷	OOO'CET)	300,010,020	(40,	æ (/o/	(452,401,140) \$	(112,418,105)
securities				7.	.402		7,402
						(33,980,053)	(33,980,053)
49	145,000	₩	380,878,828	\$ (33)	385) \$	(527,381,199)	\$(146,390,756)
securities				-14	.931		(14,931)
						(119,847,215)	119,847,215
60	145,000	€9	380,878,828	\$ (48,	316) \$	(647,228,414)	\$(266,252,902)
	w - w	\$ 145,000 \$ 145,000	\$ 145,000 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	Capital S & S	Capital Compreh. (Loss) In (Los	Capital Comprehensive (Loss) Income US Dollars Unaudited \$ 380,878,828 \$ (40,787) \$ 7,402 \$ 380,878,828 \$ (33,385) \$ -14,931 \$ 380,878,828 \$ (48,316) \$	Capital Comprehensive Ea (Loss) Income US Dollars UNAUdited \$ 380,878,828 \$ (40,787) \$ 7,402 \$ 380,878,828 \$ (33,385) \$ -14,931 \$ 380,878,828 \$ (48,316) \$

VP, Chief Financial Officer

Date of Approval